News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
|
Followers
|
64
|
Posters
|
|
|
Posts (Today)
|
0
|
Posts (Total)
|
4466
|
|
Created
|
09/25/06
|
Type
|
Free
|
| Moderators | |||
A/S: 700,000,000
O/S: 53,239,440 as of May 12, 2009
Transfer Agent: Continental Stock Transfer & Trust until 12-31-2010. Current transfer agent unknown.
10-Q May 13, 2009: www.sec.gov/Archives/edgar/data/1190132/000114420409025963/0001144204-09-025963-index.htm
USA:
China Biopharma, Inc.
PO Box 6303
Freehold, NJ 07728 USA
Phone: 609-651-8588
Fax: 609-228-4301
Email:
contact.chbo@gmail.com
Former China office:
China Biopharma, Inc.
173 Yugu Lu, Zhongtian DaSha 16-L
Hangzhou, 310007 China
Now in this office resides Zhongchai Machinery, www.zhongchaimachinery.com . Peter Wang, CEO of China BioPharma Inc., is also President of Zhongchai Machinery.
News:
April 10, 2006. Techedge Inc. Signs Definitive Agreement to Acquire China BioPharma Ltd.
http://findarticles.com/p/articles/mi_m0EIN/is_2006_April_10/ai_n16120462/
May 30, 2006. Techedge Inc acquired China BioPharma Ltd.
www.alacrastore.com/mergers-acquisitions/China_Biopharma_Inc-2542974
July 6, 2006. Techedge Board Has Approved for its New Name As China Biopharma Inc.
findarticles.com/p/articles/mi_m0EIN/is_2006_July_6/ai_n26917143/
July 18, 2006. Techedge Projects $10,000,000 in sales for 2006.
findarticles.com/p/articles/mi_m0EIN/is_2006_July_18/ai_n26926871/
August 10, 2006. China Biopharma Inc. merged into Techedge. (filing)
On July 14, 2006, Techedge and China Biopharma, Inc, a Delaware corporation and a wholly-owned subsidiary of Techedge executed a Plan and Agreement of Merger whereby the parties agreed to merge CB with and into Techedge, with Techedge being the surviving corporation. By virtue of, and effective upon the consummation of the Merger, the Certificate of Incorporation of the Company was amended to change its name from "Techedge, Inc." to "China Biopharma, Inc." The merger became effective on August 10, 2006.
January 16, 2007. Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd. is a subsidiary of China BioPharma Limited. (Businessweek report)
investing.businessweek.com/businessweek/research/stocks/private/snapshot.asp
March 25, 2007. China Biopharma Signed Distribution Agreement with Takeda Pharmaceutical.
http://www.pharmagazette.com/2007/03/china_biopharma_signed_distrib.html#more
China Biopharma Inc.'s Chinese subsidiary - Hainan CITIC Biopharmaceutical Development Co., Ltd. - has entered into a distribution agreement with Takeda Pharmaceutical Company, Ltd. As part of Takeda's goal to expand sales channels in Asia, China Biopharma has begun distributing Serrapeptase tablets, and the agreement with Takeda calls for China Biopharma to distribute additional drugs as hey become available.
Based in Osaka, Japan, Takeda is the largest pharmaceutical company in Japan which discovers, develops, manufactures and markets a broad range of superior pharmaceutical products.
March 27, 2008. China Biopharma Reaches Agreement with a Regional Pharma to Launch New Pharmaceutical Products.
www.pharmaceuticalonline.com/article.mvc/China-Biopharma-Reaches-Agreement-With-A-Regi-0001
September 15, 2008. China Biopharma Inc. Effects 1 for 100 Reverse Stock Split
www.biospace.com/news_story.aspx
December 26, 2008. China Biopharma Inc. Issues Corporate Information Update
www.biospace.com/news_story.aspx
November 4, 2009. Novartis to expand its human vaccines presence in China through proposed acquisition of a majority stake in Zhejiang Tianyuan:
January 31, 2011. Novartis-Zhejiang Tianyuan acquisition - A $172.92 M
(Australian link, Australian dollars?)
http://au.legalbusinessonline.com/deals/novartis-zhejiang-tianyuan-acquisition/2793
March 16, 2011. Zhejiang Tianyuan Alters the Name into Novartis Tianyuan.
http://www.sinocast.com/readbeatarticle.do?id=55021
March 17, 2011. Novartis Buys 85% Shares of China's Largest Private Vaccine Maker.
www.eeo.com.cn/ens//homepage/haedlinescanner/2011/03/17/196601.shtml
March 17, 2011. Novartis gets stake approval.
www.chinadaily.com.cn/bizchina/2011-03/17/content_12185656.htm
March 22, 2011. Novartis completes acquisition of majority stake in Zhejiang Tianyuan expanding vaccines presence in China.
www.novartis.com/newsroom/media-releases/en/2011/1498805.shtml
WHAT IS IN CHINA BIOPHARMA, Inc.?
China Biopharma's Partners:
TAKEDA
Takeda, the largest pharmaceutical company in Japan, recognizes the strength of CHBO's distribution network. Takeda is trying to grow their distribution channels in China and had signed a distribution deal with CHBO.
Takeda Products: http://www.takeda.com/products/ethical-drugs/article_896.html
China Biopharma Forms Distribution Agreement with World-Renowned Japanese Pharmaceutical Company Takeda
DASEN® serrapeptase (anti-inflammatory) http://www.chinabiopharma.com.cn/Index_2_Read.asp?PressType=1&ID=61
SPECIALTY PHARMACEUTICAL PRODUCTS
The company has worked with the Japanese pharmaceutical company, Takeda Pharmaceutical Company, Ltd. ("Takeda"), the largest pharmaceutical company in Japan. With global headquarters located in Osaka, Japan, Takeda specializes in the research and development of breakthrough drugs, and has marketing operations throughout U.S., Europe, and Asia. In Japan, Takeda has also built a strong presence in the over-the-counter (OTC) drugs market, in which it holds the second largest domestic share.
After distributing its products for about ten months on a trial basis, both parties are quite happy with the outcomes and decide to continue this relationship and we will commit more resources and increase our capabilities to carry Takeda's products.
SOONFAST PHARMACEUTICAL
China Biopharma Reaches Agreement to Introduce A New Antiviral Drug: http://www.chinabiopharma.com.cn/Index_2_Read.asp?PressType=1&ID=69
China Biopharma has worked with Soonfast Pharmaceutical Science & Technology Co., Ltd. ("Soonfast") to introduce a new antiviral medicine into the overseas market including the United States and European countries. This all-natural product has been approved in China for external use to treat human papillomavirus ("HPV") and herpes simplex virus ("HSV"). Tests have shown an inhibitory effect on the growth of HPV and HSV, and the medicine can reduce the infection from HPV and HSV by 90% within only 2-3 days. Experiments have also proved that the herbal can kill all of the HPV types 6/11/16/18 and 33.
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Disclaimer:*****The moderator and assistant moderators of this forum are not professional financial/investment consultants and reserve the there right to any opinion and share no responsibilty or liable in there or other persons buying or selling stock investment deciscions and ask that persons or investors be advised in seeking there own individual professional financial counseling or due diligence before buying or selling of any stocks.*****
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
Charts:
http://stockcharts.com/h-sc/ui?s=CHBO&p=W&yr=3&mn=0&dy=0&id=p00740380098
http://stockcharts.com/h-sc/ui?s=CHBO&p=D&yr=0&mn=10&dy=0&id=p61179325147
http://stockcharts.com/h-sc/ui?s=CHBO&p=D&yr=0&mn=3&dy=0&id=p17074483516
